EGFR in melanoma: clinical significance and potential therapeutic target (Q39586032)

13 September 2017

EGFR in melanoma: clinical significance and potential therapeutic target (English)

1 reference

13 September 2017

6

1 reference

13 September 2017

7

Marc Bracke

1 reference

13 September 2017

Barbara Boone

1

1 reference

13 September 2017

Koen Jacobs

2

1 reference

13 September 2017

Liesbeth Ferdinande

3

1 reference

13 September 2017

Jasmien Taildeman

4

1 reference

13 September 2017

Jo Lambert

5

1 reference

13 September 2017

Patrick Pauwels

8

1 reference

13 September 2017

Lieve Brochez

9

1 reference

13 September 2017

24 February 2011

1 reference

Journal of Cutaneous Pathology

13 September 2017

1 reference

13 September 2017

38

1 reference

13 September 2017

492-502

1 reference

13 September 2017

6

1 reference

Specificity within the EGF family/ErbB receptor family signaling network

13 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Epidermal growth factor receptor (EGFR) signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Increased epidermal growth factor receptors in melanocytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

HER3 is a determinant for poor prognosis in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Differential oncogenic potential of activated RAS isoforms in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

Cutaneous melanoma susceptibility and progression genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.2011.01673.X

10.1111/J.1600-0560.2011.01673.X

21 January 2018

Identifiers

DOI

1 reference

release_rox4obmv2vhpnokvyspo63sa7e

13 September 2017

0 references

1 reference